A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

NCT03369236 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

C3 Glomerulopathy
C3 Glomerulonephritis
Dense Deposit Disease

Interventions

DRUG: Danicopan
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.